Cell Death Differ:TBC1D17-Rab5通路影响2型糖尿病相关的葡萄糖摄取

2021-05-28 xiaozeng MedSci原创

2型糖尿病是一种与年龄相关的疾病,其在全球范围内影响着超过400万人。

2型糖尿病是一种与年龄相关的疾病,其在全球范围内影响着超过400万人。作为该疾病的主要特征,胰岛素抵抗会导致葡萄糖稳态的失调。

既往研究显示,Glut1(葡萄糖转运蛋白1)的表达下调和胰岛素反应性Glut4的转运受损均会促进胰岛素抵抗作用的发生。除胰岛素外,运动是骨骼肌中Glut4转运的另一种重要的生理刺激。AMP和ADP含量的增加会激活细胞中的能量传感器AMPK(AMP活化激酶),并随后介导运动/肌肉收缩对葡萄糖摄取的影响,然而其潜在的分子机制尚不清楚。

因此,进一步的了解AMPK介导的信号转导通路可为治疗与2型糖尿病相关的胰岛素抵抗提供新的见解和潜在的治疗靶标。


在该研究中,研究人员发现,在骨骼肌和成肌细胞中AMPK均能够正调控Rab5的激活。Rab5是一种小的GTP酶,是核内体融合、转运和生物发生的重要调节因子,其参与调节Glut4的转运。

AMPK激活Rab5

进一步的研究显示,被确定为Rab5潜在相互作用伴侣的TBC1D17是Rab5的新型GTPase激活蛋白(GAP)。TBC1D17-Rab5通路能够调节Glut1、Glut4和转铁蛋白受体的转运。而TBC1D17分别通过其RBC5结构域或N末端1–306区域(N-Ter)与Rab5或AMPK相互作用的。


此外,AMPK能够磷酸化TBC1D17的第168位Ser丝氨酸残基,该残基与预测的AMPK共有基序匹配。TBC1D17的N-Ter结构域能够通过与TBC结构域直接相互作用而充当抑制区。该蛋白的Ser168磷酸化能够促进分子内的相互作用,从而增强TBC1D17的自抑制作用。

Ser168磷酸化增强TBC1D17的自抑制作用

综上,该研究结果表明,TBC1D17能够充当连接AMPK和Rab5的分子桥,并揭示了调节TBC/RabGAP激活的相关分子机制。TBC1D17-Rab5通路或可成为治疗代谢性疾病和衰老的一个潜在的靶标。


原始出处:

Rao, X.S., Cong, X.X., Gao, X.K. et al. AMPK-mediated phosphorylation enhances the auto-inhibition of TBC1D17 to promote Rab5-dependent glucose uptake. Cell Death Differ (27 May 2021).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1872219, encodeId=f37318e22191a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 26 03:31:25 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962529, encodeId=17eb19625297c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 14 06:31:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784268, encodeId=648b1e8426878, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Tue Sep 14 01:31:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531743, encodeId=76b51531e43c6, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sun May 30 13:31:25 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043618, encodeId=077b10436185c, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat May 29 01:31:25 CST 2021, time=2021-05-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1872219, encodeId=f37318e22191a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 26 03:31:25 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962529, encodeId=17eb19625297c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 14 06:31:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784268, encodeId=648b1e8426878, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Tue Sep 14 01:31:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531743, encodeId=76b51531e43c6, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sun May 30 13:31:25 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043618, encodeId=077b10436185c, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat May 29 01:31:25 CST 2021, time=2021-05-29, status=1, ipAttribution=)]
    2021-09-14 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1872219, encodeId=f37318e22191a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 26 03:31:25 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962529, encodeId=17eb19625297c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 14 06:31:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784268, encodeId=648b1e8426878, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Tue Sep 14 01:31:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531743, encodeId=76b51531e43c6, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sun May 30 13:31:25 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043618, encodeId=077b10436185c, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat May 29 01:31:25 CST 2021, time=2021-05-29, status=1, ipAttribution=)]
    2021-09-14 isabellayj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1872219, encodeId=f37318e22191a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 26 03:31:25 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962529, encodeId=17eb19625297c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 14 06:31:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784268, encodeId=648b1e8426878, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Tue Sep 14 01:31:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531743, encodeId=76b51531e43c6, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sun May 30 13:31:25 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043618, encodeId=077b10436185c, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat May 29 01:31:25 CST 2021, time=2021-05-29, status=1, ipAttribution=)]
    2021-05-30 cy0328
  5. [GetPortalCommentsPageByObjectIdResponse(id=1872219, encodeId=f37318e22191a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 26 03:31:25 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962529, encodeId=17eb19625297c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Sep 14 06:31:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784268, encodeId=648b1e8426878, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Tue Sep 14 01:31:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531743, encodeId=76b51531e43c6, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sun May 30 13:31:25 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043618, encodeId=077b10436185c, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat May 29 01:31:25 CST 2021, time=2021-05-29, status=1, ipAttribution=)]
    2021-05-29 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Nutrients:基于杏仁的低碳水化合物饮食可改善2型糖尿病患者的抑郁和糖代谢情况

低碳水化合物饮食(LCD)有益于2型糖尿病(T2DM)的糖代谢,可有效降低抑郁症。杏仁是一种常见的坚果,能有效改善机体的高血糖和抑郁症状。近日,一项随机对照试验探究了基于杏仁的LCD(a-LCD)对T

Clin Res Cardiol:性别、年龄和种族对糖尿病合并急性冠脉综合征患者冠状动脉和心力衰竭事件的影响

老年和非白人患者发生心力衰竭的风险较高,在女性中有更明显的趋势,而只有非白人患者发生MACE的风险更高

Liver Int:直接抗病毒治疗对合并慢性肝炎或肝硬化的2型糖尿病的长期血糖控制的影响

直接抗病毒治疗对合并慢性肝炎或肝硬化的2型糖尿病的长期血糖控制的影响

BMJ:2型糖尿病新型药物疗法

目前,全世界有超过4.63亿成年人患有糖尿病,预计到2045年,患病人数将上升至7亿。与此同时,糖尿病每天导致150万人死亡,其中60%以上可归因于心血管疾病,并大大增加了非致命性心血管事件的风险。为

J Clin Endocrinol Metab:超低热量饮食可显著降低肥胖患者的体重,改善肠道菌群组成和机体代谢

肥胖与多种合并症密切相关,包括2型糖尿病(T2D)、炎症、肝脏和胰腺内的多余脂肪、高血压和某些类型的癌症。肥胖症管理可以推迟从糖尿病前期到T2D的进展,并导致T2D的持续缓解。流行病学研究表明,含有乳